Bilirubin From Heme Oxygenase-1 Attenuates Vascular Endothelial Activation and Dysfunction

Keiichi Kawamura, Kazunobu Ishikawa, Youichiro Wada, Satoshi Kimura, Hayato Matsumoto, Takahide Kohro, Hiroyuki Itabe, Tatsuhiro Kodama, Yukio Maruyama

Objective—Heme oxygenase-1 (HO-1), the rate-limiting enzyme of heme degradation, has recently been considered to have protective roles against various pathophysiological conditions. Since we demonstrated that HO-1 overexpression inhibits atherosclerotic formation in animal models, we examined the effect of HO modulation on proinflammatory cytokine production, endothelial NO synthase (eNOS) expression, and endothelium-dependent vascular relaxation responses.

Methods and Results—After HO-1 induction by heme arginate (HA), vascular endothelial cell cultures were exposed to oxidized low-density lipoprotein (oxLDL) or tumor necrosis factor-α (TNF-α). HA pretreatment significantly attenuated the production of vascular cell adhesion molecule-1, monocyte chemotactic protein-1, and macrophage colony-stimulating factor, suggesting that HO-1 induction attenuates proinflammatory responses. In addition, HO-1 overexpression also alleviated endothelial dysfunction as judged by restoration of attenuated eNOS expression after exposure to oxLDL and TNF-α. Importantly, impaired endothelium-dependent vascular relaxation responses in thoracic aortic rings from high-fat–fed LDL receptor knockout mice were also improved. These effects were observed by treatment with bilirubin not by carbon monoxide.

Conclusions—These results suggest that the antiatherogenic properties of HO-1 may be mediated predominantly through the action of bilirubin by inhibition of vascular endothelial activation and dysfunction in response to proinflammatory stresses. (Arterioscler Thromb Vasc Biol. 2005;25:155-160.)

Key Words: heme oxygenase ■ oxidized LDL ■ endothelial nitric oxide synthase ■ bilirubin ■ carbon monoxide

Vascular endothelial cell activation by oxidized LDL (oxLDL) and cytokines such as tumor necrosis factor-α (TNF-α) is considered to play an essential role in the development of atherosclerotic lesions.1 Activated endothelial cells produce adhesion molecules, chemokines, and growth factors such as vascular cell adhesion molecule-1 (VCAM-1), monocyte chemotactic protein-1 (MCP-1), and macrophage colony-stimulating factor (MCSF).2–4 Numerous studies have shown that these molecules promote multiple steps in the formation of atherosclerotic lesion.1,3,4 Endothelial dysfunction, which is associated with decreased bioavailability of NO from endothelial NO synthase (eNOS), is also considered to play an important role in atherogenesis.1,5 NO formed by eNOS has been shown to contribute to vascular smooth muscle cell relaxation and inhibition of platelet aggregation.1 Heme oxygenase (HO) catalyzes the rate-limiting step of heme degradation in mammals.6 The products of the reaction are biliverdin, carbon monoxide (CO), and free iron. It has been suggested that biliverdin and CO have cytoprotective effects against various cellular stresses.7–9 We demonstrated that the inducible form of HO (HO-1) is induced in cultured vascular endothelial cells, smooth muscle cells, and macrophages by oxidized low-density lipoprotein (oxLDL), and that high expression of HO-1 results in attenuation of monocyte chemotaxis by oxLDL.9 In fact, HO-1 is expressed in atherosclerotic lesions.10,11 We also demonstrated that overexpression of HO-1 inhibits the formation of atherosclerotic lesions by inhibiting lipid peroxidation and by affecting NO metabolism.11,12 These data suggest that HO-1 as an intrinsic antioxidant plays an important role against atherogenesis. However, it is still unknown1 which proinflammatory molecules are involved in the biological action of HO-1 and2 which HO-1 reaction product is predominantly responsible for vascular endothelial protection.

In this study, we screened for changes in genes after heme arginate (HA) treatment of vascular endothelium using cDNA microarray analyses to eliminate the possibility that use of heme derivatives to induce HO-1 may result in effects on genes other than the HO-1 gene. These analyses revealed that the HA treatment used in this study had the strongest effect on...
the HO-1 gene and that effects on other genes were minimal. Endothelial HO-1 overexpression significantly attenuated production of inflammatory mediators and reversed the decrease in eNOS by oxLDL and TNF-α. In addition, HO-1 overexpression also improved the impaired vasodilatory responses of aortic segments treated with oxLDL. Importantly, these effects on vascular endothelium were predominantly observed by treatment with bilirubin not by CO. These results suggest the possibilities that HO-1 via the action of bilirubin is involved in suppression of endothelial dysfunction and activation in response to proinflammatory stresses.

Methods

Reagents

TNF-α was obtained from R&D systems and HA from Huhtamäki Oy Pharmaceuticals. Tricarbonyldichlororuthenium (II) dimer ([Ru(CO)3Cl2]) was from Stream Chemicals. All other reagents were obtained from Sigma-Aldrich unless indicated otherwise. HA, Sn-protoporphyrin IX (SnPP IX), and bilirubin solutions were prepared in the dark.

Cell Culture

Human aortic endothelial cells (HAECs) were purchased from Clonetics. In all experiments, cells were used at passage 4-6. HO-1 activities were modulated by either 1 to 10 μmol/L HA for 16 hours or 10 μmol/L SnPP IX for 2 hours as described previously. To generate CO in cell cultures, tricarbonyldichlororuthenium (II) dimer ([Ru(CO)3Cl2]), a CO-releasing compound, was used. The amount of CO released was assessed spectrophotometrically by measuring the conversion of deoxymyoglobin to carbonmonoxy myoglobin. The amount of CO released from 50 μmol/L [Ru(CO)3Cl2] in culture medium was ∼38.7±2.5 μmol/L in medium (data not shown). Cells pretreated with bilirubin were not exposed to light to prevent degradation.

Microarray Analysis of cRNA and Quantitative Analysis

HAECs were cultured with 5 μmol/L HA and harvested after 16 hours. First-strand cDNA was generated with 10 μg of mRNA using T7-linked oligo(dT) primer (Takara). After second-strand synthesis, in vitro transcription was performed with biotinylated UTP and CTP (Enzo Diagnostics). Resultant cRNA was purified on an affinity resin column (RNasy; Qiagen). Biotinylated cRNA (40 μg) was fragmented and hybridized to oligonucleotide gene chip, human FL array (Affymetrix), and 6416 genes were analyzed as described previously. Quantitative analyses were performed with GeneChip Software (Affymetrix). The average differences and fold changes were defined and calculated as described previously.

Lipoprotein Isolation and Modification

LDL was isolated from the sera of normal blood donors by density-gradient ultracentrifugation. OxLDL was prepared by incubating freshly prepared LDL at 37°C for 24 hours in PBS (pH 7.4) containing 50 μmol/L CuSO4 and then dialyzing extensively against PBS.

Western Blot Analysis

Cell cultures and mouse aorta were washed, lysed, and homogenized in 10 mmol/L Tris-HCl (pH 7.4) containing 0.1% sodium dodecyl sulfate and a protease inhibitor cocktail (Boehringer Mannheim). A total of 20 μg of cell lysate and tissue homogenates was electrophoresed, transferred to a nylon membrane (MSI), and hybridized with 32P-labeled rat HO-1 and VCAM-1 cDNAs as described previously.

ELISA for Inflammatory Mediators

ELISA for VCAM-1, MCP-1, and M-CSF was performed with kits (R&D Systems) using conditioned media from HAEC cultures according to manufacturer protocol.

RNA Extraction and Northern Blot Analysis

Total RNA was isolated with TRIzol reagent (GIBCO/BRL). A total of 20 μg of total RNA was electrophoresed, transferred to a nylon membrane (MSI), and hybridized with 32P-labeled rat HO-1 and VCAM-1 cDNAs as described previously.

Plasma Lipids and Lipid Peroxidation Assay

Blood was collected from mice fasted overnight. Total plasma cholesterol, triglyceride, and high-density lipoprotein (HDL) concentrations were determined enzymatically. Plasma lipid hydroperoxides were measured by the methylene blue hemoglobin method.

Animal Handling and Vascular Relaxation Response

All animal experiments were conducted in accordance with the guidelines of the Fukushima Medical University animal research committee. Two- to 3-month-old female LDL-receptor knockout mice with a C57BL/6J background (C57BL/6J-Ldlrtm1Her) were fed a regular chow diet (C group; n=6) or a chow diet (C group; n=6). The high-fat diet was started 1 week before the experiment for vascular endothelium response. To overexpress HO-1, HA (25 mg/kg) was injected intraperitoneally every other day during high-fat diet (HF+HA group; n=6). To examine the effects of CO, CO at 60 ppm was administered in a chamber for 2 hours per day during high-fat diet (HF+CO group; n=6). To examine the effects of bilirubin, bilirubin (25 mg/kg) was injected intraperitoneally every other day during high-fat diet (HF+BR group; n=6).

To examine endothelium-dependent vascular relaxation responses, isolated thoracic aortic strips were prepared. After euthanization, the descending thoracic aorta was excised, washed, and cut into aortic rings (2 mm). Aortic rings were then suspended in organ chambers in the Krebs' buffer saturated with a 95% O2, 5% CO2 gas mixture. After equilibration for 90 minutes, the aorta was contracted with 1 μmol/L phenylephrine, and the endothelium-dependent and -independent responses were examined with acetylcholine (10−9 to 10−7 mol/L) and sodium nitroprusside (10−7 to 10−3 mol/L).

Data Analysis

All values are expressed as means±SD. Significant difference was determined by 1-way ANOVA with the Fisher post hoc test. P<0.05 was considered significant.

Results

HO-1 Induction in Vascular Endothelial Cells by HA

To induce HO-1 in cultured vascular endothelial cells, we treated them with micromolar concentrations of HA. Figure 1A shows the dose-dependent induction of HO-1 protein and enzyme activity by HA. We did not observe any apparent toxic effects of HA as judged by trypan blue exclusion or lactate dehydrogenase release (data not shown).
To exclude pleiotropic effects of HA on genes other than HO-1, 6416 genes were screened with the GeneChip System before and after treatment with 5 μmol/L HA for 16 hours, the condition used to induce HO-1 in this study. The Table shows the genes, which were induced >3-fold or were downregulated <2-fold by HA. HO-1 was the gene that responded most and was induced up to 13-fold, although HA also upregulated several other genes such as NAD(P)H:menadione oxidoreductase and cytochrome P450 (CYP1A2), which have an antioxidant response element (ARE). In contrast, HA treatment reduced expression levels of 4 genes to <50%. The Table also includes the genes that are thought to be involved in endothelial activation or dysfunction, but HA treatment did not significantly change their expression. These results suggest that HA treatment induces HO-1 in a relatively specific manner.

HO-1 Induction Attenuates Proinflammatory Responses to Oxidized LDL and TNF-α in Vascular Endothelial Cells

To determine the effect of HO-1 on proinflammatory responses in vascular endothelium, we first examined the production of VCAM-1 in response to TNF-α (2 ng/mL) by ELISA (Figure 1B). HA pretreatment (5 μmol/L) itself did not induce the production and secretion of VCAM-1 into the conditioned media. Interestingly, VCAM-1 production after TNF-α exposure was significantly reduced by pretreatments with 1, 5, and 10 μmol/L HA. These effects were abolished by HO inhibitor SnPP IX (10 μmol/L). In addition, HA pretreatment also attenuated induction of VCAM-1 mRNA expression caused by TNF-α. Total RNA was prepared 6 hours after TNF-α exposure.

The effects of HA pretreatment were also observed in our cDNA microarray analysis (Table). A total of 6416 human genes were screened with GeneChip System (Affymetrix) before and after treatment with 5 μM HA for 16 hours. The Table shows the genes, which were induced or downregulated by HA pretreatment.

### cDNA Microarray Analysis of Human Vascular Endothelial Cells
#### After Heme Arginate Treatment

<table>
<thead>
<tr>
<th>Accession No.</th>
<th>Gene</th>
<th>Average Difference</th>
<th>Fold Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>X06985</td>
<td>HO-1</td>
<td>2202.2</td>
<td>13.0</td>
</tr>
<tr>
<td>J09334</td>
<td>NAD(P)H:menadione oxidoreductase</td>
<td>326.6</td>
<td>4.5</td>
</tr>
<tr>
<td>M31667</td>
<td>Cytochrome P450 (CYP1A2)</td>
<td>99.9</td>
<td>3.8</td>
</tr>
<tr>
<td>M60244</td>
<td>E16</td>
<td>199.9</td>
<td>3.3</td>
</tr>
<tr>
<td>X12451</td>
<td>Pro-cathepsin L</td>
<td>158.7</td>
<td>3.1</td>
</tr>
</tbody>
</table>

### Genes of interest

- MCP-1: Hs303649
- VCAM-1: M30257
- MCSF: M37435
- eNOS: M93718
- HO-1: X06985
- Chemokine HCC-1: Z49269
- Protein tyrosine phosphatase (CIP2): L25876
- Hexokinase II (HK3): U51333
- Adipocyte lipid-binding protein: J02874
- Cyclooxygenase-2: M90100

### Figure 1

**A**  HO-1 induction by HA and bilirubin treatment results in attenuation of VCAM-1 production caused by TNF-α in HAECS. A, HO-1 protein expression (left panel) and activity (right panel) after HA treatment. Cells were exposed to 0, 1, 5, and 10 μmol/L HA for 16 hours and analyzed by Western blotting and HO assay. B, HA and bilirubin pretreatment attenuates VCAM-1 production caused by TNF-α. Cells were pretreated with HA for 16 hours to induce HO-1 or with SnPP IX (10 μmol/L) for 2 hours to inhibit HO-1. To observe the effects of CO and bilirubin, cells were pretreated with [Ru(CO)3Cl2]2 (50 μmol/L), or bilirubin (5 μmol/L) in the dark for 2 hours, respectively. Then cells were exposed to TNF-α (2 ng/mL) for 12 hours, washed 3 ×, and incubated in fresh media for another 12 hours. Media collected between 12 and 24 hours after TNF-α exposure were analyzed for VCAM-1 production (ng/mL) by ELISA in duplicate. Data shown are representative for 3 independent experiments. **P<0.001; **P<0.005. C, HA pretreatment attenuates VCAM-1 mRNA expression caused by TNF-α. Total RNA was prepared 6 hours after TNF-α exposure.

**B**  VCAM-1 secretion (ng/mL) by ELISA in duplicate. Data shown are representative for 3 independent experiments. **P<0.001; **P<0.005. C, HA pretreatment attenuates VCAM-1 mRNA expression caused by TNF-α. Total RNA was prepared 6 hours after TNF-α exposure.

**C**  VCAM-1 production (ng/mL) by ELISA in duplicate. Data shown are representative for 3 independent experiments. **P<0.001; **P<0.005.

### Figure 1

**A**  HO-1 induction by HA and bilirubin treatment results in attenuation of VCAM-1 production caused by TNF-α in HAECS. A, HO-1 protein expression (left panel) and activity (right panel) after HA treatment. Cells were exposed to 0, 1, 5, and 10 μmol/L HA for 16 hours and analyzed by Western blotting and HO assay. B, HA and bilirubin pretreatment attenuates VCAM-1 production caused by TNF-α. Cells were pretreated with HA for 16 hours to induce HO-1 or with SnPP IX (10 μmol/L) for 2 hours to inhibit HO-1. To observe the effects of CO and bilirubin, cells were pretreated with [Ru(CO)3Cl2]2 (50 μmol/L), or bilirubin (5 μmol/L) in the dark for 2 hours, respectively. Then cells were exposed to TNF-α (2 ng/mL) for 12 hours, washed 3 ×, and incubated in fresh media for another 12 hours. Media collected between 12 and 24 hours after TNF-α exposure were analyzed for VCAM-1 production (ng/mL) by ELISA in duplicate. Data shown are representative for 3 independent experiments. **P<0.001; **P<0.005. C, HA pretreatment attenuates VCAM-1 mRNA expression caused by TNF-α. Total RNA was prepared 6 hours after TNF-α exposure.

**B**  VCAM-1 secretion (ng/mL) by ELISA in duplicate. Data shown are representative for 3 independent experiments. **P<0.001; **P<0.005. C, HA pretreatment attenuates VCAM-1 mRNA expression caused by TNF-α. Total RNA was prepared 6 hours after TNF-α exposure.

**C**  VCAM-1 production (ng/mL) by ELISA in duplicate. Data shown are representative for 3 independent experiments. **P<0.001; **P<0.005.
HO-1 Induction Preserves eNOS Expression After Exposure to OxLDL and TNF-α

To examine whether the antiatherogenic and vasculoprotective effects of HO-1 are via the effect of eNOS expression, we pretreated HAECs with HA and observed the resultant expression of eNOS after exposure to oxLDL and TNF-α (Figure 2). Untreated cells expressed a significant level of eNOS protein, whereas there was little expression of HO-1 mRNA and protein (Figure 2A, lane 1). Treatment with native LDL (50 μg/mL) had little effect on eNOS expression (Figure 2A, lane 3), whereas treatment with oxLDL (50 μg/mL) reduced eNOS expression accompanied by HO-1 induction (Figure 2A, lane 4). Interestingly, HO-1 overexpression by HA pretreatment significantly preserved eNOS expression (Figure 2A, lane 5). The effect of HO-1 induction on restoration of eNOS expression was abolished by cotreatment with SnPP IX (10 μmol/L), an HO inhibitor (Figure 2A, lane 6). Figure 2B shows the dose-dependent effect of HO-1 on attenuation of eNOS expression by TNF-α. HO-1 induction also recovered this attenuation.

To determine the HO-1 products responsible for preservation of eNOS expression, cells were pretreated with either 50 μmol/L [Ru(CO)₃Cl₂], a CO-releasing compound, or 5 μmol/L bilirubin for 2 hours (Figure 2A, available online at http://atvb.ahajournals.org), and then the cells were exposed to oxLDL (50 μg/mL) for 16 hours. Whereas [Ru(CO)₃Cl₂] treatment did not preserve eNOS expression, bilirubin treatment significantly preserved eNOS expression after exposure to oxLDL (Figure 2A). In addition, this effect was not inhibited by SB203580, an inhibitor of p38 mitogen-activated protein (MAP) kinase (Figure 2B).

HO-1 Induction Improves Impaired Endothelium-Dependent Vascular Relaxation

After we observed significant effects of HO-1 induction and bilirubin on the endothelial responses to oxLDL and TNF-α, we next examined whether these also affect endothelium-dependent vascular relaxation responses. To observe the changes of endothelium-dependent vascular relaxation response, isolated thoracic aortic rings from LDL-receptor knockout mice were prepared (Figure 3A). Aortic rings from mice fed high-fat diet for 1 week (HF group) showed impaired vasodilatory responses to acetylcholine compared with control (C group). Interestingly, aortic rings from mice fed high-fat diet and pretreated with HA (HF+HA group) showed improved vasodilatory responses on high-fat HF diet. Bilirubin pretreatment (HF+BR group) resulted in similar improvement, whereas CO exposure (HF+CO group) did not have apparent effects (Figure 3A). In contrast, there were no significant differences among the 4 groups in endothelium-independent relaxation responses (Figure 3B). To examine whether the improvement of vascular relaxation responses are mediated by restoration of eNOS by HA and bilirubin treatments, levels of HO-1 and eNOS expression in the aorta were examined (Figure 3C). After high-fat diet feeding, eNOS expression was significantly attenuated. In contrast, modest induction of HO-1 was observed. Importantly, HA pretreatment augmented this HO-1 induction and restored eNOS expression. Similar effects were confirmed after treat-
Recent study showed that HA is less toxic. Indeed, treatment with micromolar concentrations of HA did not have any inhibitory effects on lipid peroxidation in atherosclerotic animal models. Significant reduction of plasma lipid hydroperoxides was observed in mice treated with HA (Figure 3D). There were no significant differences in total plasma cholesterol, triglyceride, and HDL concentrations among the groups fed high-fat diet (data not shown).

Discussion
In this study, we examined whether vascular endothelial HO-1 expression is involved in the endothelial activation and insufficiency elicited by proinflammatory stresses, which are considered to be events essential for atherogenesis. Our results suggest that there are conditions under which HO-1 expression significantly suppresses production of proinflammatory mediators and reverses impaired eNOS expression in response to oxLDL and TNF-α.

To induce HO-1 in cultured endothelial cells, we used low concentrations of HA instead of hemin chloride because a recent study showed that HA is less toxic. Indeed, treatment with micromolar concentrations of HA did not have any injurious effects. We first examined the changes in gene expression in endothelial cells before and after treatment with 5 μmol/L HA for 16 hours, the conditions used to induce HO-1. A cDNA microarray analysis revealed that HO-1 was the gene most strongly upregulated, and that several other genes that have an ARE element also responded positively to this treatment (Table). Importantly, the microarray also revealed that HA treatment did not generate significant changes in other genes that may affect atherogenic processes in vascular endothelium. For instance, transcriptional changes of adhesion molecules, growth factors, and redox-sensitive transcription factors such as nuclear factor-κB were not significant (Table). Similarly, the eNOS gene considered to have antiatherosclerotic properties was not significantly altered by HA treatment.

Recent studies provide evidence that HO-1 functions as an intrinsic defense system in cardiovascular disorders. The protective effects of HO-1 may be attributed to its biological actions in vascular endothelium because endothelial HO-1 induction by HA significantly attenuated production of VCAM-1, MCP-1, and MCSF (Figures 1 and I) and preserved eNOS expression (Figures 2 and II) in response to TNF-α and oxLDL. The functional improvement of the endothelium-dependent vasodilatory response was also confirmed (Figure 3).

Cytoprotective effects of HO-1 have been observed recently in many kinds of cells, such as cardiomyocytes, hepatocytes, and fibroblasts, as well as in vascular endothelial cells. In this study, we tried to examine the biological effects of the products of HO-1 in vascular endothelium. To observe the direct effects of CO, we treated cells with 50 μmol/L ([Ru(CO)₃Cl]₂), a CO-releasing compound, and did not observe apparent biological effects, suggesting that CO is not an HO-1 product that protects endothelium (Figure IIA), although recent studies have suggested there are multi-potent actions of CO in endothelium. However, it is possible that CO produced from endothelium may regulate other cells in the artery wall. CO from endothelial cells may function to relax smooth muscle cells under conditions of insufficient NO bioavailability and suppress reactive oxygen species generation in macrophages infiltrated into the artery wall. Indeed, this is supported by a recent report that CO suppresses proinflammatory cytokine production via inhibition of the c-Jun N-terminal kinase pathway in macrophages.

In this study, protective effects on vascular endothelium were observed with another HO-1 product, bilirubin. A physiological concentration of bilirubin suppressed activation of proinflammatory genes such as VCAM-1, MCP-1, and MCSF (Figures 1 and I), restored eNOS expression (Figures 2 and II), and improved endothelium-dependent vascular relaxation responses (Figure 3). Bilirubin seems to alleviate the effects of oxidative stresses on endothelium, which is considered to be a central factor in atherosclerosis. Because the anti-inflammatory action of CO in macrophages has been shown recently to be mediated via the p38MAP kinase pathway, we examined the effect of SB203580, an inhibitor of p38MAP kinase, on the action of bilirubin (Figure IIB). However, inhibition of the p38MAP kinase pathway did not abolish the effect of bilirubin. Thus, bilirubin seems to relieve endothelial dysfunction independent of this pathway. Previous studies have also indicated that bilirubin is a potent inhibitor of monocyte adhesion to vascular
endothelium. Our study indicates that eNOS is one of the molecular targets of bilirubin in vascular endothelium, and that bilirubin functionally improves vasodilatory responses, although protective effects of bilirubin to other proinflammatory stimuli such as lipopolysaccharides and angiotensin II should also be explored (Figure 3). In conclusion, this study revealed that the antiatherosclerotic properties of HO-1 are mediated through effects on vascular endothelium and that these effects are predominantly caused by bilirubin.

Acknowledgments
This work was supported by a grant-in-aid (14570682 and 16590703) from the Ministry of Education, Science, and Culture of Japan.

References
Bilirubin From Heme Oxygenase-1 Attenuates Vascular Endothelial Activation and Dysfunction
Keiichi Kawamura, Kazunobu Ishikawa, Youichiro Wada, Satoshi Kimura, Hayato Matsumoto, Takahide Kohro, Hiroyuki Itabe, Tatsuhiko Kodama and Yukio Maruyama

Arterioscler Thromb Vasc Biol. 2005;25:155-160; originally published online October 21, 2004; doi: 10.1161/01.ATV.0000148405.18071.6a
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2004 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/25/1/155

Data Supplement (unedited) at:
http://atvb.ahajournals.org/content/suppl/2004/12/28/01.ATV.0000148405.18071.6a.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/
A

<table>
<thead>
<tr>
<th>Treatment</th>
<th>eNOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>oxLDL</td>
<td>- + + + +</td>
</tr>
<tr>
<td>[Ru(CO)₃Cl₂]₂</td>
<td>- - + -</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>- - - +</td>
</tr>
</tbody>
</table>

B

<table>
<thead>
<tr>
<th>Treatment</th>
<th>eNOS</th>
</tr>
</thead>
<tbody>
<tr>
<td>oxLDL</td>
<td>- + + + - -</td>
</tr>
<tr>
<td>Bilirubin</td>
<td>- - + + + -</td>
</tr>
<tr>
<td>SB203580</td>
<td>- - - + - +</td>
</tr>
</tbody>
</table>
Online-Figure Legends

Fig. I. HO-1 induction by HA and bilirubin pretreatment attenuates MCP-1 and MCSF production caused by oxLDL and TNFα in HAEC. Cells were pretreated with 1, 5 and 10 µM HA for 16 hours or with SnPP IX (10 µM), [Ru(CO)₃Cl₂]₂ (50 µM), and bilirubin (5 µM) for 2 hours. Then, cells were exposed to oxLDL (50 µg/ml) (A, C) or TNFα (2 ng/ml) (B, D) for 3 hours, washed, incubated in fresh media for another 3 hours. MCP-1 (A, B) and MCSF (C, D) production (pg/ml) were analyzed by ELISA with conditioned media in duplicate. Data shown are representative for three (A, C) and four (B, D) independent experiments. *; p<0.001, **; p<0.005.

Fig. II. Preservation of eNOS expression after exposure to oxLDL is not attributed to CO but to bilirubin. (A, B) Cells were pretreated with either 50 µM [Ru(CO)₃Cl₂]₂ or with 5 µM bilirubin for 2 hours. Then, cells were exposed to oxLDL (50 µg/ml) for 16 hours. Cells pretreated with [Ru(CO)₃Cl₂]₂ were exposed to a cold light to release CO. eNOS protein expression were examined by Western blotting. SB203580, an inhibitor of p38 MAP kinase, was added 2 hours before bilirubin pretreatment. Data shown are representative for three independent experiments.